Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DPII: Discovery Partners Int'l -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (31)	10/24/2005 12:03:53 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 111

Slimming down probably makes it look a bit as if DPI has little confidence that they'll sign Pfizer or any other big customer soon. "Any value added" stuff above the line? (these are the competitors listed in quarterly filing of a year ago) Assay development and screening (Cerep, Evotec OAI AG, Pharmacopeia and Tripos) Compound libraries and lead optimization (Albany Molecular Research, Pharmacopeia, Array Biopharma, Evotec OAI AG, Biofocus and ArQule) With scads and scads of little biotechs I'm not sure that doing any of this makes a viable business. ____________________________________ But I suppose these are the lousier bits: Informatics (Accelrys and Tripos) And this looks like a lot of the stuff they discarded: Combinatorial chemistry instruments, including Argonaut and Mimotopes; Not sure if this went too... Gene profiling (Affymetrix and Gene Logic)